{"id":"NCT01186939","sponsor":"Celgene","briefTitle":"An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)","officialTitle":"AZA PH GL 2003 CL 001 - Extension A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04-01","primaryCompletion":"2009-09-01","completion":"2009-09-01","firstPosted":"2010-08-23","resultsPosted":"2010-09-21","lastUpdate":"2019-11-14"},"enrollment":40,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myelodysplastic Syndromes"],"interventions":[{"type":"DRUG","name":"Azacitidine","otherNames":["AZA"]}],"arms":[{"label":"Azacitidine","type":"EXPERIMENTAL"}],"summary":"At the conclusion of study AZA PH GL 2003 CL 001 (NCT00071799), eligible participants could be enrolled in an optional extension phase in order to continue treatment with azacitidine until it became commercially available; the continued treatment was for ethical and safety reasons only and not to provide additional efficacy data.","primaryOutcome":{"measure":"Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period","timeFrame":"43- 68 months","effectByArm":[{"arm":"Azacitidine","deltaMin":39,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":22,"countries":["Australia","Bulgaria","France","Germany","Greece","Hungary","Italy","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":["19230772","20026804","23585522","30016552","20451404","30114559","30037860","29933073","30091166","30442503","30406952","30518537","30636526","30584089","30653424","21656747"],"seeAlso":["http://www.clinicaltrials.gov/ct2/results?term=NCT00071799"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":40},"commonTop":["Thrombocytopenia","Neutropenia","Anaemia","Diarrhoea","Injection site reaction"]}}